Physician profile
David E Dobratz
NPI 1245226166
$12,961.89
in general payments reported to CMS, 2019-2025
67 companies · $1,642 in 2025
The $1,642 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,298 · 2020: $329 · 2021: $1,938 · 2022: $2,580 · 2023: $2,168 · 2024: $2,005 · 2025: $1,642.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,815.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,815.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,136.83 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Novo Nordisk INC | $1,170.61 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $1,007.69 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $924.18 | 2019-2025 | Evenity, Prolia, Repatha |
| Pfizer INC. | $762.40 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $598.29 | 2019-2025 | Airsupra, Farxiga, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $563.28 | 2019-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $523.96 | 2019-2025 | Xifaxan |
| Antares Pharma, INC. | $443.00 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Merck Sharp & Dohme LLC | $354.39 | 2019-2024 | Gardasil 9, Capvaxive, Gardasil |
| Otsuka America Pharmaceutical, INC. | $352.52 | 2021-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $309.95 | 2019-2025 | |
| Abbott Laboratories | $235.41 | 2021-2025 | Freestyle Libre 3, Afinion 2 |
| Takeda Pharmaceuticals U.S.A., INC. | $228.14 | 2019-2025 | Vpriv, Trintellix |
| Biohaven Pharmaceutical Holding Company LTD. | $185.58 | 2022 |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Dobratz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.